The pharmaceutical M&A landscape in India is experiencing a resurgence, with Q3 2025 recording a surge in deal value, driven by strategic consolidations and a focus on high-quality operating assets, particularly in formulations and CDMO. Investors are prioritizing scale, innovation-led investments, and integrated models.
This document presents a comprehensive, authoritative listing for a turn-key pharma facility for sale Rudrapur, Uttarakhand, a key industrial zone. This offering aligns perfectly with current market trends seeking established, compliant, multi-product formulation units in emerging markets.
Turn-Key Non-Beta Lactam Formulation Unit
This is an exclusive opportunity to acquire a fully operational, multi-product facility with active manufacturing licenses, established infrastructure, and comprehensive GMP/GLP compliance documentation in the high-growth industrial hub of Uttarakhand, India.
| Key Feature | Specification / Data from Documents | Citation |
| Location | Sector 3, IIE, Sidcul, Pantnagar, Rudrapur, Udham Singh Nagar, Uttarakhand 263153, India. Situated 4 km from Rudrapur city and 8 km from Pantnagar Airport. Green belt area, free from dust & smoke. | |
| Operational Since | Commissioned for commercial production since June 2007. | |
| Total Area | Land Area:approx 2000Sq. meters (approx 21520 Sq. Ft.). Factory Building:approx 30528 Sq Ft area (in Three floors). | |
| Manufacturing License | Drug Manufacturing License No. xx/UA/2007 (Form No. 25) & xx/UA/SC/P-2007 (Form No. 28). Valid up to 04-04-2027. | |
| Certifications | WHO-GMP-GLP, ISO 9001: 2015 Certified Company. All activities are carried out as per Schedule -M of the Indian Drugs & Cosmetics Act. | |
| Facility Structure | Ground Floor, First Floor, and Second Floor. Reinforced Cement Concrete (RCC) frame structure. Core areas have Epoxy Flooring and Epoxy Paint with coving. | |
| Products/Dosage Forms | Non-Beta Lactam (No hazardous activities like pesticides/bulk drugs manufactured on site): Tablets, Capsules, Oral Liquid (Syrup/Suspension), External Preparation (Ointment). |
Production & Capacity Data
The facility has significant installed and operational capacity for multiple dosage forms, representing a strong, revenue-ready asset.
| Category of Preparation | Capacity Per Month (Installed) | Annual Capacity (Installed) | Capacity/Shift Basis (Operational) |
| Tablets | 10.50 Cr. | 126 Cr. | 2.0 Million |
| Capsules | 2.08 Cr. | 24.96 Cr. | 1.0 Million |
| Oral Liquid (Ltrs.) | 528,000 Ltrs. | 6,336,000 Ltrs. | 75 Thousand Ltrs. |
| Cream & Ointments (Kgs.) | 62,400 Kgs. | 748,800 Kgs. | 30 Thousand units (External Prep) |
| Lotions & Solution (Ltrs.) | 260,000 Ltrs. | 3,120,000 Ltrs. | – |
Core Equipment & Infrastructure in Pharma Facility for Sale Rudrapur
The facility boasts an extensive list of process and QC equipment, indicating a high level of operational readiness and compliance.
1. Air Handling Units (AHUs) & HVAC System
- Total 25 AHUs detailed across Ground, First, and Second Floors (GF-AHU-01 to SF-AHU-025).
- Dedicated AHUs for critical areas: Sampling, Dispensing, Liquid Manufacturing, Bottle Filling, Granulation, Compression, Coating, Capsule Filling, Blister/Strip Packing, and Ointment Manufacturing.
- HVAC system designed with positive pressure in corridors, air changes, temperature control and humidity control (NMT 65% RH).
2. Production Equipment (Key Machinery)
- Tablet/Capsule: Double Rotary Tableting Machines (45 Station – Max. 1,29,000 tab/hr, 37 Station – Max. 50,400 tab/hr), Fluid Bed Dryer (120 Kg), Double Cone Blender (120 Kg), Mass Mixer (400 Ltr), Conventional Coater (Max. 120 kgs), Capsule Filling Machine.
- Liquid/Syrup: Liquid Manufacturing Tank (3.5 KL), Sugar Malting Tank (2.5 KL), Homogenizer (7.5 Hp), Liquid Filling Machine (Eight Head – 120 Bottle/Min), Bottle Washing Machine (120 Bottle/Min).
- External Prep (Ointment): Vacuum Emulsifier (200 L), Mixing Tank (300 L), Ointment Filling Machine.
- Packaging: Blister Packing Machine (Max.300 Pack/Min), Strip Packing Machine (Max. 50 pack/min), ALU ALU (Max. 300 Pack/Min).
3. Quality Control (QC) & Micro Lab Instruments
- HPLC (Auto/Manual): Waters 2487 (3 Units in QC Instrument Room I).
- Spectro Photometer UV-visible (Shimadzu).
- Testing Equipment: Dissolution Test Apparatus (Sotax), Friability Test Apparatus, Melting Point Test Apparatus, Karl Fischer Titrator Apparatus, Gas Chromatography (Shimadzu).
- Micro Lab: BOD Incubator (2 Nos), Hot Air Oven, Vertical Autoclave, Laminar Air Flow.
4. Utility Systems
- Water System: Centralized Purified Water Plant (500 liters/hr capacity) with RO, EDI unit, UV Sanitizer System, and storage in SS.316 L tanks maintained at $80^{\circ}C$ under continuous circulation.
- Power: Diesel Generator (250 KVA) for power backup.
- Air: Oil-free Air compressor (200 cfm).
- Waste: Effluent Treatment Plant (ETP) with a capacity of $3 KL/day$.
Compliance, Documentation & Workforce
The facility operates within a robust quality management system (QMS), which is crucial for due diligence.
| Area | Detail / Data from Documents | Citation |
| QMS | Independent Quality Assurance (QA) Department for decision-making. Systems cover cGMP/GLP, Vendor Qualification, Change Control, Self-Inspection (twice per year). | |
| Validation | Process, sterilization, and cleaning processes are validated. HVAC, Water System, and Compressed air systems are validated. Process validation requires three consecutive batches within limits. | |
| Documentation Control | Master documents are stored and controlled by the QA Documentation Cell. Batch records are stored for at least one year after expiry or five years from manufacturing date. | |
| Workforce | Total 123 employees working in the unit. Technical staff includes: Production (8), QC (8), QA (9), Engineering (4), Store (3). | |
| Key Personnel | Approved Chemist responsible for Technical activities. QA Manager is responsible for batch release. |
Market Trends & Buyer Actionable Tips (2025)
The Indian pharma sector saw $3.5 billion in deals in Q3 2025, with M&A surging 57% in volume. The focus is shifting towards formulations, CDMO, and integrated models, moving past just API manufacturing. Acquiring this Rudrapur facility offers an immediate entry point into the lucrative Indian formulations market.
Actionable Due Diligence Checklist for This Asset
For buyers, due diligence must go beyond financials to secure a high-value asset:
- Regulatory: Verify the longevity and scope of the 36/UA/2007 & 39/UA/SC/P-2007 licenses (valid until 2027). Check for all recent compliance violations (if any) and warning letters.
- HVAC & Water System Validation: Request the latest revalidation reports (measured periodically) for the HVAC system and the 80oC purified water loop system.
- Process Capability: Review the three consecutive validation batch records for a representative Tablet, Liquid, and Ointment product to confirm stated capacities and process control adherence.
- IP & Documentation: Scrutinize the SOPs on “Vendor Quality Audit” and the “Change Control Program”—these indicate the robustness of the quality culture.
Valuation & Negotiation Edge
- EBITDA Multiples: Generic Manufacturing units typically command an EBITDA multiple in the range of 9.9x to 12x. This asset’s multi-product capability (Tablets, Capsules, Liquids, Ointments) and full compliance status should position it toward the higher end.
- Strategic Premium: Given the global shift towards supply chain resilience, a fully compliant, multi-dosage facility in a low-risk, established industrial location like Sidcul (away from polluting industries) warrants a strategic premium for its turn-key status and immediate operational readiness.
Legal & Regulatory Guidance
The acquisition of a pharma unit necessitates a change in ownership, which requires compliance with the Drugs and Cosmetics Act of 1940 and the State Drug Controller’s requirements.
- License Transfer: Post-acquisition, the new entity must apply to the State Drug Controller for the re-issuance of the Manufacturing Drug License in its name, proving continuous compliance with quality standards and adequate facilities.
- Key Personnel Approval: The continuity of the Approved Chemist and other technical staff is critical for license transfer.
- Documentation Handover: Ensure all required documents are transferred, including the latest Site Master File (Effective Date: 28/12/2023, Next Review Date: 27/12/2026), Batch Manufacturing/Packaging Records (for 5 years/1 year post-expiry), and all Calibration/Validation Records.
FAQ
What is the current business model?
The company is engaged in the manufacture of products on a contract basis. This provides a foundation for quick revenue generation post-acquisition via existing or new contract development and manufacturing (CDMO) agreements.
What kind of cleaning validation is in place?
Cleaning procedures are validated by direct surface sampling (swab method) and indirect sampling (rinse solutions). Effectiveness is evaluated by visual, chemical residue, and microbial contamination tests.
What is the policy for rejected materials?
Rejected raw/packaging materials are separated, affixed with ‘REJECTED’ labels, and transferred to a secured “Rejection” area under lock and key, with QA deciding the final fate (destroy/return).
What are the storage conditions for Finished Goods?
Finished Goods are stored in a controlled environment (warehouse) at 25oC+-2oC and 50+-5% Relative Humidity. Dispatches are ensured on a First-In, First-Out (FIFO) basis.
How is facility maintenance handled?
Utilities are maintained by in-house engineering/utility staff. Maintenance records are kept in equipment logbooks.
Conclusion & Next Steps
This offering represents a rare opportunity to acquire a validated, multi-product Non-Beta Lactam formulation facility(Pharma Facility for sale Rudarpur) in a prime Indian industrial zone. With active licenses, robust quality systems (WHO-GMP-GLP, ISO 9001:2015), comprehensive documentation, and immediate production capacity in Tablets, Capsules, Liquids, and Ointments, this asset is poised for immediate value creation in the highly strategic 2025 M&A market.
Ready for the next step? We manage the entire acquisition process from due diligence review to license transfer.
Would you like me to send a confidential information memorandum (CIM) outlining the detailed financial profile, site schematics (Annexures VI & VII), and full equipment list (Annexure VIII) for this facility?
